We thank Avades and colleagues for the opportunity to expand on our expert panel consensus statement (Lee, B. P. et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nat. Rev. Gastroenterol. Hepatol. 21, 626–645 (2024))¹ to highlight the important role of persons with lived experience of alcohol use disorder (AUD) and/or alcohol-associated liver disease (ALD), their caregivers and their advocates in clinical trials (Avades, T. et al. An expert panel Consensus Statement on ALD without experts by experience. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-024-00994-1 (2024))². Including these voices is critical to guide the design of clinical trials, recruitment and retention efforts, and, most importantly, the implementation of findings for the individuals most affected by these diseases.

我们感谢 Avades 及其同事有机会扩展我们的专家小组共识声明 （Lee， BP et al. 设计临床试验以解决酒精使用和酒精相关性肝病：专家小组共识声明。Nat. Rev. 胃肠醇。肝醇。21， 626–645 （2024））¹ 强调有酒精使用障碍 （AUD） 和/或酒精相关性肝病 （ALD） 生活经历的人、他们的护理人员和他们在临床试验中的倡导者的重要作用（Avades， T. et al.专家小组 关于 ALD 的共识声明，没有经验专家。Nat. Rev. 胃肠醇。肝醇。https://doi.org/10.1038/s41575-024-00994-1 （2024））².纳入这些声音对于指导临床试验的设计、招募和保留工作至关重要，最重要的是，为受这些疾病影响最严重的个体实施研究结果。